Our lab is excited to announce a new collaboration with Tezcat Biosciences, supported by a Phase II SBIR award from the National Cancer Institute. Together, we will conduct advanced preclinical testing of TZT-102 in KRAS-mutant pancreatic cancer, leveraging patient-derived xenograft (PDX) models to explore new therapeutic opportunities. This partnership bridges biotech innovation with academic translational research, with the shared goal...